
SELLAS Life Sciences Stock Soars 166% After Phase 3 REGAL Leukemia Vaccine Trial Meets Its Survival Goal, With a Further 5% Gain Reported on 18 November
SLS about +166% to $19.84 on 17 Nov from $7.47. REGAL hazard ratio 0.59, p=0.035. Median survival 24.0 vs 14.7 months. BLA planned for H1 2027.
Updated: 19 Nov 2026 • 10:27 am
Posted by:

Quick Answer
SELLAS Life Sciences, listed on NASDAQ as SLS, rose about 166% to $19.84 on 17 November 2026 after its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia met its primary overall survival endpoint. The hazard ratio was 0.59 with a p-value of 0.035, meaning a 41% lower risk of death, and median survival was 24.0 months against 14.7 months. The company plans a biologics license application in the first half of 2027. A report also points to a further gain of about 5% on 18 November. Approval is not assured, and the stock remains highly volatile.
SELLAS Life Sciences stock has become one of the biggest healthcare moves of the week after the company reported that its Phase 3 REGAL trial of a leukemia vaccine hit its main survival goal.
This guide covers the trial numbers, the price reaction, the short interest behind the move, the regulatory path and the risks. SLS is listed in the United States, so the figures are in US dollars and come from company and media reports.
Click Here – Get Free Investment Predictions
REGAL Trial Result at a Glance
| Item | Reported result |
|---|---|
| Trial | Phase 3 REGAL |
| Candidate | Galinpepimut-S (GPS), a cancer vaccine |
| Condition | Acute myeloid leukemia (AML) |
| Primary endpoint | Overall survival, met |
| Hazard ratio | 0.59, which means 41% lower risk of death |
| P-value | 0.035 |
| Median survival | 24.0 months versus 14.7 months |
| Announced | 17 November 2026 |
The median survival gap is 9.3 months (our arithmetic), and the treatment arm lived about 1.6 times as long as the comparison arm at the median. A p-value of 0.035 clears the usual 0.05 threshold, though not by a wide margin, which is why analysts will wait for the full dataset. Keep a written note of the price level you are using while tracking the SELLAS rally, before any money is committed.
AML is an aggressive blood cancer with limited options after remission, so a trial that improves survival is significant for the field. A short list of questions helps when thinking about SLS shares, since small differences in timing can change the outcome.
How the Stock Reacted
| Measure | Figure |
|---|---|
| Prior close (16 November) | $7.47 |
| Price after the news | About $19.84 |
| Gain | About 166% (our arithmetic gives 165.6%) |
| Volume | 57 to 72 million shares |
| Average volume | About 6.9 million shares |
| Short interest | About 28% of the float |
Volume was roughly 8 to 10 times the normal level, which shows how many traders rushed in. Short interest of about 28% means a large share of the float was sold short, and covering by those traders can add fuel to a jump like this one. Wait for the closing figures before drawing a firm conclusion on SLS shares, since volumes often tell the real story.
A report also says the stock rose a further 5% on 18 November. We could not confirm the closing price for that session, so check a live quote for the current level. Time horizon decides how much weight to give to SLS shares, before any money is committed. Revisit your assumptions after each new filing when tracking SELLAS shares, and keep notes so the reasoning can be reviewed later.
What GPS Is and Why the Result Matters
Galinpepimut-S is an immunotherapy designed to help the immune system recognise and attack leukemia cells. REGAL compared it with a control approach in patients with AML, and the survival difference is the first Phase 3 evidence of its kind for this vaccine. A checklist keeps emotion out of any decision following the SELLAS rally, and weigh it against your own time horizon. Sector peers give a useful yardstick when reading this AML vaccine trial result, because a rushed decision is rarely a better one.
| Stage | Status |
|---|---|
| Phase 3 primary endpoint | Met |
| Next step | Biologics license application planned for the first half of 2027 |
| Regulator | US Food and Drug Administration |
| Approval | Not guaranteed |
The application will bring detailed safety and efficacy data under review. Regulators look at the full package, so a positive headline does not guarantee approval. Sector peers give a useful yardstick when reading the SELLAS rally, while treating third-party opinions as inputs only.
Explore healthcare stocks with the Univest Screener
SELLAS Life Sciences Stock Outlook: What Must Happen Before Approval
| Milestone | What to watch |
|---|---|
| Full data release | Subgroup results, safety and dropout rates |
| Filing | Acceptance of the application and its timing |
| Regulator feedback | Questions on trial design or manufacturing |
| Funding | Cash runway for filing and launch costs |
| Partnerships | Any deal that shares commercial costs |
Biotech stocks often move in stages. After a binary result, the next catalysts are data presentations, regulatory milestones and financing. BlackRock is reported to hold about 6.8%, a sign of institutional interest, though a holding does not predict direction. Scenario thinking is more useful than prediction when reading about this AML vaccine trial result, then compare it with the sector average.
Investors should treat these dates as moving targets, because delays are common in drug development and any change can swing the share price sharply. Note the source and date of every figure when writing about this AML vaccine trial result, because markets reprice quickly on new information. Separate facts from opinion while reading the SELLAS rally, and scale any position to the risk you can absorb.
Risks Behind a 166% Jump
| Risk | Why it matters |
|---|---|
| Binary outcome | One regulatory decision can reset the price either way |
| Short squeeze effect | Covering can inflate prices beyond what the data justify |
| Capital raise | Small drug developers often sell shares after a surge, diluting holders |
| Single asset | Value depends heavily on one product |
| Volatility | Daily moves of 20% or more are possible |
The result is a major milestone, but the path to a marketed drug is long. After a rise this size, much of the good news is already in the price. Revisit your assumptions after each new filing when tracking this AML vaccine trial result, and weigh it against your own time horizon.
Univest does not give buy or sell calls, and this article is general information. Size any position to your own risk limits. A fair review looks at both the positives and the risks of SLS shares, and look for confirmation across several data points. Liquidity and bid-ask spreads deserve a look when reading SELLAS shares, and weigh it against your own time horizon.
Notes for Indian Investors
SLS trades on NASDAQ in US dollars, so Indian investors need a broker that offers US market access and must stay within the Reserve Bank of India's remittance rules. Currency movement adds a second layer of risk on top of the stock's own volatility. Keep a written note of the price level you are using while tracking SELLAS shares, and do not assume that a past pattern will repeat.
US market hours run late in the Indian evening, and prices can move sharply on news after Indian markets close. Check your broker's rules on order types, tax treatment and fees before placing any trade. A fair review looks at both the positives and the risks of the SELLAS rally, and do not assume that a past pattern will repeat. A fair review looks at both the positives and the risks of this AML vaccine trial result, and remember that targets and levels are not guarantees.
Download the Univest iOS App or Univest Android App to track global themes and Indian pharma stocks.
Conclusion
SELLAS Life Sciences delivered the result its investors wanted, with a hazard ratio of 0.59 and a median survival of 24.0 months, and the shares rose about 166% to $19.84. A filing is planned for the first half of 2027. Volume and delivery data add useful context when watching SELLAS shares, since small differences in timing can change the outcome. Small position sizes keep mistakes affordable when acting on SLS shares, while treating third-party opinions as inputs only.
The stock now prices in a good deal of success. Full data, regulatory review, financing and a heavy short position make volatility the main feature to expect. Reading the fine print is a good habit before settling on a view of SELLAS shares, and avoid chasing a move that has already happened. Treat any single headline as incomplete when reading SLS shares, because liquidity can thin out near the close.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What did the SELLAS REGAL Phase 3 trial show?
Ans. The REGAL trial of galinpepimut-S in acute myeloid leukemia met its primary overall survival endpoint, with a hazard ratio of 0.59 and a p-value of 0.035. Median survival was 24.0 months in the treatment group against 14.7 months in the comparison group.
How much did SELLAS stock rise after the trial result?
Ans. The shares rose about 166%, from a prior close of $7.47 to roughly $19.84 on 17 November 2026, on volume far above the 6.9 million average. A report also pointed to a further gain of about 5% on 18 November, which we could not confirm.
What is galinpepimut-S?
Ans. Galinpepimut-S, or GPS, is a cancer vaccine candidate designed to train the immune system to target leukemia cells. SELLAS tested it in a Phase 3 trial in acute myeloid leukemia, and the company plans to file for US approval in the first half of 2027.
Why did short interest matter in the SELLAS rally?
Ans. Short interest was about 28% of the float, so many traders had bet on a decline. When the trial result arrived, those traders had to buy shares to close positions, which can push prices higher and faster than the news alone would justify.
Can Indian investors buy SELLAS Life Sciences shares?
Ans. SLS is listed on NASDAQ, so Indian investors need a broker with US market access and must comply with Reserve Bank of India remittance limits and tax rules. Currency swings and US trading hours add risks, and Univest does not give buy or sell calls on foreign stocks.
Does a positive Phase 3 result mean the drug will be approved?
Ans. No. A positive primary endpoint is a major step, but regulators review the full safety and efficacy package, manufacturing and trial conduct. Approval is not assured, delays are common, and financing needs can dilute existing shareholders before any launch.
Recent Articles

BofA Fund Manager Survey India Turns Overweight for the First Time Since January: Net 5% Positive After Net 32% Underweight in August
20 November 2026

FPI Record Monthly Inflow Nears Rs 1 Lakh Crore in November 2026: Why Foreign Investors Turned Buyers and What Could Slow the Turnaround
20 November 2026

IndusInd Bank Share Price Rally: Stock Jumps 8.6% to Rs 1,003 on 20 November 2026 as Nifty Bank Hits a Record and Volume Surges 4.5 Times
20 November 2026

India Large Caps AI Shift: Can Nifty Heavyweights Gain as Global Money Rotates Out of AI Trades? MSCI India Up 11% From Its October Low
20 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
BofA Fund Manager Survey India Turns Overweight for the First Time Since January: Net 5% Positive After Net 32% Underweight in August
FPI Record Monthly Inflow Nears Rs 1 Lakh Crore in November 2026: Why Foreign Investors Turned Buyers and What Could Slow the Turnaround
IndusInd Bank Share Price Rally: Stock Jumps 8.6% to Rs 1,003 on 20 November 2026 as Nifty Bank Hits a Record and Volume Surges 4.5 Times
India Large Caps AI Shift: Can Nifty Heavyweights Gain as Global Money Rotates Out of AI Trades? MSCI India Up 11% From Its October Low
NSE Share Price Target of Rs 2,381 From Anand Rathi: Exchange Stock Hits a Record Rs 2,251, Up 37% From Its October Low

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





